-
11.发明申请METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH 审中-公开用FISH检测循环肿瘤细胞中IGF1R / Chr 15的方法公开(公告)号：US20090258365A1
公开(公告)日：2009-10-15
申请号：US12409190
申请日：2009-03-23
申请人： Leon W.M.M. Terstappen , Brad Foulk
发明人： Leon W.M.M. Terstappen , Brad Foulk
IPC分类号： C12Q1/68
CPC分类号： G01N33/57492 , C12Q1/6841 , C12Q1/6886 , C12Q2600/156 , G01N2333/71
摘要： The present invention describes methods and probe composition for an automated FISH assay of a blood sample containing circulating tumor cells expressing the IGF-1R gene. The assay provides genetic analysis of suspect circulating tumor cells that have been identified after immunomagnetic selection and fluorescent labeling. Using unique, repeat-free probes to the IGF-1R locus and a chromosome 15 reference probe, cell lines expressing an aberrant number of IGF-1R and Chr 15 signals were detected, including one cell line with a low level of IGF-1R amplification. The ability to directly examine the genetic profile of IGF-1R on circulating tumor cells may provide an automated means for assessing disease and patient response to therapy.
摘要翻译： 本发明描述了含有表达IGF-1R基因的循环肿瘤细胞的血液样品的自动FISH测定方法和探针组合物。 该测定提供了在免疫磁选择和荧光标记后鉴定的可疑循环肿瘤细胞的遗传分析。 对IGF-1R基因座和染色体15参考探针使用独特的无重复探针，检测到表达异常数量的IGF-1R和Chr 15信号的细胞系，包括具有低水平IGF-1R扩增的一个细胞系 。 直接检测IGF-1R在循环肿瘤细胞上的遗传图谱的能力可以提供评估疾病和患者治疗反应的自动化手段。
-
12.发明申请Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH) 审中-公开使用免疫磁性富集和荧光原位杂交（FISH）监测进行性癌症遗传变化的血液检测公开(公告)号：US20080113350A1
公开(公告)日：2008-05-15
申请号：US11595504
申请日：2006-11-09
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106
摘要： Amplification and overexpression of theHER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between the primary tumor and metastases. Therefore, patients with HER-2 negative primary tumors will rarely receive anti-HER-2 antibody therapy. A very sensitive blood test is used to capture circulating tumor cells (CTC's) and evaluate their HER-2 gene status by FISH evaluation. The HER-2 status of the primary tumor and corresponding CTC's is used to assess the ratio of CTC's as a reliable surrogate marker. HER-2 expression of 10 CTC's is sufficient to make a definitive diagnosis of the HER-2 gene status for the whole population of CTC's in patients with recurrent breast cancer.
摘要翻译： 乳腺癌中HER-2癌基因的扩增和过表达在疾病过程中被认为是稳定的，并且在原发性肿瘤和转移灶之间是一致的。 因此，HER-2阴性原发性肿瘤患者很少接受抗HER-2抗体治疗。 使用非常敏感的血液测试来捕获循环肿瘤细胞（CTC），并通过FISH评估评估其HER-2基因状态。 原发肿瘤和相应的CTC的HER-2状态用于评估CTC作为可靠替代标记的比例。 10 CTC的HER-2表达足以对复发性乳腺癌患者的CTC的全部群体进行HER-2基因状态的确定诊断。
-
搜索结果
12 条记录 (耗时 0.024 秒)
